EMERGENT BIOSOLUTIONS INC. Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Modification of Contract
EMERGENT BIOSOLUTIONS INC. (EBS) reported Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Modification of Contract of $200.00 million for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-05.
Discontinued › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract · last filed 2021-11-05
- EMERGENT BIOSOLUTIONS INC. contract with customer, liability, cumulative catch-up adjustment to revenue, modification of contract for the quarter ending 2021-09-30 was $200.00M.
| Period end | Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Modification of Contract 3 month |
|---|---|
| 2021-09-30 | $200.00M 10-Q · filed 2021-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |